Decades of History Tell Anything: Biotech Near $50 Set to Soar
A cash-generative biotech near $50 is drawing buyers amid a market shift toward defensible healthcare names. Here’s w...
Bear markets test retirement portfolios. This piece explains how risk parity may influence drawdowns and resilience, plus practical steps for retirees.
28,208 articlesA cash-generative biotech near $50 is drawing buyers amid a market shift toward defensible healthcare names. Here’s w...
Bitcoin remains the anchor as June approaches, with institutional buyers scooping up BTC during pullbacks. This piece...
Bitdeer’s May 2026 update shows a spike in BTC mined alongside a steep drop in BTC held, underscoring the tension bet...
London moves away from wallet limits toward a single market cap on sterling stablecoins, signaling a friendlier frame...
Choosing a broad-market ETF can feel like splitting hairs. This guide compares VTI and SCHB on cost, exposure, and re...
A Georgia-based accessory maker will pay $1.75 million in restitution to Buffalo shooting victims’ families and halt ...
You’ve bought a few rental properties, but the real work starts now. This guide delivers a step-by-step plan to optim...
A small-cap value ETF built years of academic research is beating the S&P 500 in early 2026, buoyed by a strict value...
If you’re building a simple, durable plan, understanding three core ideas around VOO can save you money and stress. T...
When Oshkosh released its latest results, the focus quickly shifted to a sharp stock move. This guide explains what h...
Step into the 2026 beauty health (skin) investing landscape. This guide translates early 2026 earnings signals into a...
Vanguard’s mid-cap ETF VO is drawing renewed attention as markets tilt toward diversification beyond mega-cap tech. T...